Celldex Therapeutics, Inc. (CLDX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
CLDX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
CLDX Revenue Analysis (2014–2025)
As of March 1, 2026, Celldex Therapeutics, Inc. (CLDX) generated trailing twelve-month (TTM) revenue of $1.5 million, reflecting significant decline in growth of -93.6% year-over-year. The most recent quarter (Q4 2025) recorded $75,000 in revenue.
Looking at the longer-term picture, CLDX's 5-year compound annual growth rate (CAGR) stands at -27.4%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $12.7 million in 2017.
Revenue diversification analysis shows CLDX's business is primarily driven by Grant (94%), and Service (6%). With over half of revenue concentrated in Grant, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including REGN (+1.0% YoY), IMNM (-4.4% YoY), and RXRX (+27.5% YoY), CLDX has underperformed the peer group in terms of revenue growth. Compare CLDX vs REGN →
Peer Comparison
Compare CLDX's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CLDXCurrent | $2M | -93.6% | -27.4% | -19160.0% | |
| REGN | $14.3B | +1.0% | +11.0% | 25.7% | |
| IMNM | $9M | -4.4% | - | -3382.4% | |
| RXRX | $75M | +27.5% | +85.4% | -867.9% | |
| NRIX | $84M | +54.0% | +36.3% | -340.2% | |
| ROIV | $29M | -56.4% | -15.6% | -3453.3% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.5M | -78.6% | $1.5M | 100.0% | $-287,400,000 | -19160.0% |
| 2024 | $7.0M | +2.0% | $-156,530,000 | -2229.8% | $-195,078,000 | -2778.9% |
| 2023 | $6.9M | +192.0% | $-111,128,000 | -1614.5% | $-154,542,000 | -2245.3% |
| 2022 | $2.4M | -49.3% | $-79,901,000 | -3389.9% | $-115,234,000 | -4889.0% |
| 2021 | $4.7M | -37.3% | $-48,660,000 | -1046.2% | $-71,243,000 | -1531.8% |
| 2020 | $7.4M | +107.6% | $-35,116,000 | -473.4% | $-63,354,000 | -854.1% |
| 2019 | $3.6M | -62.5% | $-39,099,000 | -1094.3% | $-55,031,000 | -1540.2% |
| 2018 | $9.5M | -25.2% | $-56,911,000 | -596.7% | $-156,436,000 | -1640.1% |
| 2017 | $12.7M | +87.8% | $-83,428,000 | -654.7% | $-121,527,000 | -953.7% |
| 2016 | $6.8M | +23.8% | $-95,240,000 | -1403.5% | $-132,916,000 | -1958.7% |
See CLDX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CLDX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CLDX vs AGIO
See how CLDX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CLDX's revenue growth accelerating or slowing?
CLDX revenue declined -93.6% year-over-year, contrasting with the 5-year CAGR of -27.4%. TTM revenue fell to $2M. This reverses the prior growth trend.
What is CLDX's long-term revenue growth rate?
Celldex Therapeutics, Inc.'s 5-year revenue CAGR of -27.4% reflects the variable expansion pattern. Current YoY growth of -93.6% is below this long-term average.
How is CLDX's revenue distributed by segment?
CLDX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.